Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dole PLC
NYSE:DOLE
|
IE |
Cyclacel Pharmaceuticals Inc
Cash from Operating Activities
Cyclacel Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
Cash from Operating Activities
-$8.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
Cyclacel Pharmaceuticals Inc
Glance View
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
See Also
What is Cyclacel Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-8.7m
USD
Based on the financial report for Jun 30, 2025, Cyclacel Pharmaceuticals Inc's Cash from Operating Activities amounts to -8.7m USD.
What is Cyclacel Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
7%
Over the last year, the Cash from Operating Activities growth was 24%. The average annual Cash from Operating Activities growth rates for Cyclacel Pharmaceuticals Inc have been 23% over the past three years , -2% over the past five years , and 7% over the past ten years .
